Insilico Medicine
Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease
Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech
Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate
Insilico Medicine, Menarini Group, Stemline Therapeutics, AI-generated cancer drug, Oncology drug candidate, Licensing agreement, $550 million deal